Article
Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors.
The oncologist - 1 Apr 2021
Joseph Cissimol P, Abaricia Sarah N, Angelis Michelle A, Polson Kathleen, Jones Robin L, Kang Yoon-Koo, Riedel Richard F, Schöffski Patrick, Serrano César, Trent Jonathan, Tetzlaff Eric D, Si Tuan Dong, Zhou Teresa, Doyle Ashley, Bauer Sebastian, Roche Maria, Havnaer Tracy
Abstract excerpt
BACKGROUND: Avapritinib, a novel inhibitor of KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18-mutant unresectable or metastatic gastrointestinal stromal tumors (U/M GISTs). We assessed the safety of avapritinib and provide evidence-based guidance on management of avapritinib-associated adverse events (AEs), including cognitive effects and intracranial bleeding. MATERIALS AND...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.